HomeGRFS • NASDAQ
add
Grifols SA - ADR ADR Class B
$7.21
Makalipas ang Oras ng Trabaho:(0.00%)0.00
$7.21
Sarado: Abr 25, 8:00:00 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$7.18
Sakop ng araw
$7.15 - $7.33
Sakop ng taon
$5.79 - $9.96
Market cap
5.99B USD
Average na Volume
984.18K
Sa balita
Mga Financial
Income Statement
Kita
Net na kita
(EUR) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Kita | 1.98B | 11.66% |
Gastos sa pagpapatakbo | 353.12M | 20.32% |
Net na kita | 68.97M | 76.86% |
Net profit margin | 3.49 | 58.64% |
Kita sa bawat share | — | — |
EBITDA | 495.68M | -11.49% |
Aktuwal na % ng binabayarang buwis | 60.20% | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
(EUR) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Cash at mga panandaliang investment | 1.00B | 55.40% |
Kabuuang asset | 21.41B | 1.97% |
Kabuuang sagutin | 12.80B | -5.05% |
Kabuuang equity | 8.61B | — |
Natitirang share | 680.41M | — |
Presyo para makapag-book | 0.83 | — |
Return on assets | 5.08% | — |
Return on capital | 5.79% | — |
Cash Flow
Net change in cash
(EUR) | Dis 2024info | Y/Y na pagbabago |
---|---|---|
Net na kita | 68.97M | 76.86% |
Cash mula sa mga operasyon | 514.62M | 208.54% |
Cash mula sa pag-invest | -178.31M | -28.31% |
Cash mula sa financing | -27.16M | -185.08% |
Net change in cash | 334.84M | 658.87% |
Malayang cash flow | 162.44M | 123.56% |
Tungkol
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
CEO
Itinatag
Nob 18, 1940
Website
Mga Empleyado
23,833